Filing Analysis
Fate Therapeutics reported the results of its June 12, 2026 Annual Meeting of Stockholders. All proposals were approved, including the election of directors, ratification of Ernst & Young LLP as auditors, and an increase in the 2022 Stock Option and Incentive Plan.
🚩 Red Flags
- Significant opposition to the equity plan increase: 14,304,810 shares voted against the 7,000,000 share increase, representing a notable portion of the votes cast.
📋 Key Facts
- Stockholders approved an increase of 7,000,000 shares to the 2022 Stock Option and Incentive Plan.
- Three Class I Directors (Robert S. Epstein, Karin Jooss, and Laura J. Hamill) were elected to hold office until 2029.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Executive compensation received a non-binding advisory vote of approval.
- Total shares entitled to vote were 116,281,693, with 87,134,422 shares present or represented by proxy.
Fate Therapeutics Inc. filed an 8-K to disclose the update of its corporate presentation for use at meetings and conferences, specifically mentioning the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress.
📋 Key Facts
- The filing date is June 4, 2026.
- The company updated its Corporate Presentation (Exhibit 99.1).
- The presentation is intended for use at the EULAR 2026 Congress.
Fate Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2026, via a press release. The filing serves as a standard quarterly update on the company's financial condition and results of operations.
📋 Key Facts
- Financial results for the quarter ended March 31, 2026, were announced on May 13, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The press release was included as Exhibit 99.1 to the filing.
Fate Therapeutics, Inc. reported its financial results for the fourth quarter and fiscal year ended December 31, 2025, via a press release issued on February 26, 2026.
📋 Key Facts
- The report was filed on February 26, 2026, for the period ending December 31, 2025.
- The company furnished the financial results under Item 2.02 (Results of Operations and Financial Condition).
- The press release containing specific financial figures was included as Exhibit 99.1.